Biohaven Pharmaceutical Holding Company Ltd. Stock price

Equities

BHVN

VGG111961055

Biotechnology & Medical Research

Delayed Nyse 04:00:01 2023-09-26 pm EDT Intraday chart for Biohaven Pharmaceutical Holding Company Ltd. 5-day change 1st Jan Change
17.65 USD +2.38% -2.32% -88.37%
Sales 2023 * - Sales 2024 * - Capitalization 10 853 M
Net income 2023 * -337 M Net income 2024 * -391 M EV / Sales 2023 *
-
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 *
-
P/E ratio 2023 *
-31,4x
P/E ratio 2024 *
-29,5x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float90.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.38%
Current month-88.37%
Current year-88.37%
More quotes
1 year
17.17
Extreme 17.17
152.44
3 years
17.17
Extreme 17.17
152.56
5 years
17.17
Extreme 17.17
152.56
10 years
16.50
Extreme 16.5001
152.56
More quotes
Managers TitleAgeSince
President - 2022
Chief Operating Officer - -
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member - 2022
Director/Board Member - 2022
More insiders
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
More Ratings
  1. Markets
  2. Equities
  3. Stock Biohaven Pharmaceutical Holding Company Ltd. - Nyse
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer